Literature DB >> 8989262

Dimeric inhibins in amniotic fluid, maternal serum, and fetal serum in human pregnancy.

E M Wallace1, S C Riley, J A Crossley, S C Ritoe, A Horne, M Shade, P M Ellis, D A Aitken, N P Groome.   

Abstract

Using new specific and sensitive enzyme-linked immunosorbent assays for inhibin A and inhibin B, we measured these proteins in amniotic fluid (AF), maternal serum (MS), and umbilical cord serum in normal pregnancies. Inhibin A levels in AF rose from a median (10-90th percentile) level of 615 (158.2-1124.6) pg/mL at 14 weeks to 1336.0 (489.4-2084.1) pg/mL at 20 weeks, and inhibin B rose from 216.6 (67.4-554.6) to 1078.2 (439.3-2482.2) pg/mL over the same period. In MS, inhibin A levels fell from a median (10-90th percentile) level of 177.5 (101.4-290.7) pg/mL at 10 weeks to a nadir of 111.9 (59.5-200.3) pg/mL at 17 weeks, rising again to 180.3 (74.1-327.2) pg/mL at 20 weeks. No inhibin B was detectable in MS. In 47 pairs of matched samples (14-16 weeks gestation) there was no correlation of inhibin A levels in AF with those in MS (r = 0.19; P > 0.05). In 45 term umbilical cord serum samples, no dimeric inhibin was detectable in serum from female babies, but inhibin B was detectable in male sera; the median (10-90th percentile) concentration was 167.4 (111.2-224.8) pg/mL. These data suggest that for the gestation periods studied, although the placenta secretes inhibin A, another source, probably the fetal membranes, secretes both inhibin A and inhibin B. Further, the presence of inhibin B in male fetuses is consistent with a testicular origin, suggesting that inhibin B may be important in the development of the fetal hypothalamo-pituitary-testicular axis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8989262     DOI: 10.1210/jcem.82.1.3685

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

Review 1.  Antenatal modes of surfactant administration for RDS prevention: a review.

Authors:  Adam Ostrzenski; Bartholomew Radolinski; Katarzyna M Ostrzenska
Journal:  J Natl Med Assoc       Date:  2006-03       Impact factor: 1.798

2.  Modulation of amniotic fluid activin-a and inhibin-a in women with preterm premature rupture of the membranes and infection-induced preterm birth.

Authors:  Victor A Rosenberg; Irina A Buhimschi; Antonette T Dulay; Sonya S Abdel-Razeq; Emily A Oliver; Christina M Duzyj; Heather Lipkind; Christian M Pettker; Catalin S Buhimschi
Journal:  Am J Reprod Immunol       Date:  2011-10-13       Impact factor: 3.886

3.  Umbilical Vein and Maternal Serum Inhibin A, Activin A, and Follistatin Concentrations in IUGR due to Placental Dysfunction Pregnancies.

Authors:  Sravanthi Kasam; Zongji Shen; Hui Cao; Madisetty Venkat Sudeep
Journal:  J Obstet Gynaecol India       Date:  2013-04-16

4.  Maternal serum and amniotic fluid inhibin A levels in women who subsequently develop severe preeclampsia.

Authors:  Shin-Young Kim; Hyun-Mee Ryu; Jae-Hyug Yang; Moon-Young Kim; Hyun-Kyong Ahn; Joong-Sik Shin; Jun-Seek Choi; So-Yeon Park; Jin-Mi Kim; Bom-Yi Lee; Do-Jin Kim
Journal:  J Korean Med Sci       Date:  2006-06       Impact factor: 2.153

5.  Physiologic variations of serum tumor markers in gynecological malignancies during pregnancy: a systematic review.

Authors:  Sileny N Han; Anouk Lotgerink; Mina Mhallem Gziri; Kristel Van Calsteren; Myriam Hanssens; Frédéric Amant
Journal:  BMC Med       Date:  2012-08-08       Impact factor: 8.775

6.  A Normative Model of Serum Inhibin B in Young Males.

Authors:  Thomas W Kelsey; Amy Miles; Rod T Mitchell; Richard A Anderson; W Hamish B Wallace
Journal:  PLoS One       Date:  2016-04-14       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.